“Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis” - Kither Biotech

Skip to content

Email:

info@kitherbiotech.com

Tel:

XXXXXXX

Address:

Via Nizza 52, Torino (Italia)

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

×

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

Campa et al (& Sala, Hirsch), Nature Communications.

Recent articles

Kither Biotech announces publication of new data in Science Translational Medicine
Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive Officer
Kither Biotech raises a €5.6m financing round to support the clinical development of a new drug for cystic fibrosis and other pulmonary diseases

Kither Biotech is a biopharmaceutical company developing signal transduction modulators for the treatment of rare respiratory diseases.

Linkedin Youtube

Menu

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

×

Home
About Us
Science
- Drug development
- Publications
Pipeline
- KIT2014
- KITCL27
Media
- Press releases
- Press coverage
Careers
Contact

Contact

Via Nizza 52, Torino (Italia)
info@kitherbiotech.com

Useful information

Privacy Policy
Cookie Policy

KITHER BIOTECH S.R.L. © COPYRIGHT 2021-2022. P. IVA 10615040010. DESIGN BY WEB AGENCY TORINO – WEB BRAND